CN111588757A - Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof Download PDFInfo
- Publication number
- CN111588757A CN111588757A CN201911211189.8A CN201911211189A CN111588757A CN 111588757 A CN111588757 A CN 111588757A CN 201911211189 A CN201911211189 A CN 201911211189A CN 111588757 A CN111588757 A CN 111588757A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- obstructive pulmonary
- chronic obstructive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable phase and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 10-30 parts of astragalus membranaceus, 9-20 parts of rhizoma polygonati, 5-20 parts of pericarpium citri reticulatae, 3-15 parts of honey radix stemonae, 4-15 parts of schisandra chinensis, 6-15 parts of radix paeoniae rubra and 3-15 parts of scutellaria baicalensis. In the formula, the astragalus and the rhizoma polygonati are monarch drugs, and can tonify lung qi and spleen qi; the dried orange peel and the honey radix stemonae are used as ministerial drugs, and the effects of invigorating spleen, reducing phlegm, moistening lung, descending qi and relieving cough are achieved; fructus Schisandrae chinensis is used as adjuvant drug for invigorating qi, astringing lung, and relieving cough; radix Paeoniae Rubra and Scutellariae radix are used as guiding drugs for promoting blood circulation, clearing heat and eliminating pathogenic factors. The medicines are used together to tonify the lung and the spleen, reduce phlegm and relieve cough, and fully exert the treatment advantages of the traditional Chinese medicine on chronic diseases. According to the main effective components of the medicines in the prescription, the volatile oil is extracted from the sealwort and the dried orange peel, and then the hydroxypropyl-beta-cyclodextrin inclusion is adopted to retain the volatile components in the subsequent spray drying process. Meanwhile, when the compound extraction and the macroporous resin refining are carried out in the preparation method, the high-efficiency retention of the effective components in the traditional Chinese medicine composition is ensured, the drug effect is ensured, and the dosage is reduced. The invention can effectively improve the symptoms of cough and asthma, shortness of breath, little phlegm, cold and the like in the stable period of the chronic obstructive pulmonary disease, and improve the exercise capacity and the life quality of patients.
Description
Technical Field
The invention relates to a medicine for treating lung diseases and a preparation method thereof, in particular to a traditional Chinese medicine composition for treating chronic obstructive pulmonary diseases in a stable period and a preparation method thereof, belonging to the technical field of traditional Chinese medicines.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory Disease characterized by airflow limitation, which can lead to progressive decline of lung function of patients, seriously affect the daily work and life quality of patients, and accompany cardiac insufficiency and systemic reaction in the later period. The course of COPD is generally clinically divided into a stationary phase and an acute attack phase. At present, western medicine mainly treats COPD in a stable phase through health education, rehabilitation exercise and drug treatment, commonly used drugs mainly comprise bronchodilators, glucocorticoids, antibiotics, expectorants and the like, and due to the fact that the course of the COPD in the stable phase is long, the antibiotics are used for a long time, and drug resistance, superinfection and toxic and side effects are easy to generate; while long-term inhaled hormonal therapy can reduce the number of exacerbations and improve patient health, the risk of side effects may increase.
In the stable stage of COPD, the syndrome differentiation of traditional Chinese medicine is the syndrome of deficiency of lung-spleen qi. The symptoms are as follows: patients with cough and asthma, short breath, little phlegm and plain cold are easy to catch a cold, and the traditional Chinese medicine treatment has obvious advantages, but a new traditional Chinese medicine for treating COPD (chronic obstructive pulmonary disease) in a stable period is lacked at present so as to solve the problems of repeated illness, drug resistance, side effects and the like caused by the combination of western medicines at present. According to clinical manifestations of patients, traditional Chinese medicine considers that the COPD is deficient in lung and spleen in the stable stage, and the deficiency of lung qi causes the weak defense and the exterior, which are easily invaded by pathogenic factors, so that the six exogenous pathogenic factors repeatedly attack the lung to induce the disease. If the lung disease and spleen and son consume mother's qi, the spleen fails to transport and transform, the stomach fails to receive health, the body is malnutrition, the respiratory muscles are fatigue, and the disease is difficult to recover. Through the differentiation of symptoms and prescription regulation of the traditional Chinese medicine, the treatment criteria of tonifying lung and spleen, and eliminating phlegm and stopping cough are taken, so that the symptoms are improved, the acute exacerbation is reduced, and the exercise capacity and the life quality are improved.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable phase, which is prepared by processing the following traditional Chinese medicine raw materials: astragalus root, Siberian solomonseal rhizome, dried orange peel, honey stemona root, schisandra fruit, red peony root and scutellaria root. The traditional Chinese medicine composition provided by the invention is reasonable in compatibility, adopts medicines for tonifying spleen and lung and regulating qi-flowing for eliminating phlegm for dialectical treatment, can effectively solve the problem of treatment medication of chronic obstructive pulmonary disease in a stable period, has no obvious side effect, and is reasonable in preparation process.
The technical scheme for solving the problems is as follows:
the invention relates to a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable period, which comprises the following raw material medicines in parts by weight: 10-30 parts of astragalus membranaceus, 9-20 parts of rhizoma polygonati, 5-20 parts of pericarpium citri reticulatae, 3-15 parts of honey radix stemonae, 4-15 parts of schisandra chinensis, 6-15 parts of radix paeoniae rubra and 3-15 parts of scutellaria baicalensis.
On the basis of the technical scheme, the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight:
20 parts of astragalus membranaceus, 16 parts of rhizoma polygonati, 14 parts of pericarpium citri reticulatae, 14 parts of honey radix stemonae, 11 parts of schisandra chinensis, 14 parts of radix paeoniae rubra and 11 parts of scutellaria baicalensis.
On the basis of the technical scheme, the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight:
30 parts of astragalus membranaceus, 10 parts of rhizoma polygonati, 20 parts of pericarpium citri reticulatae, 5 parts of honey radix stemonae, 15 parts of schisandra chinensis, 6 parts of radix paeoniae rubra and 14 parts of scutellaria baicalensis.
On the basis of the technical scheme, the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight:
18 parts of astragalus membranaceus, 20 parts of rhizoma polygonati, 6 parts of pericarpium citri reticulatae, 15 parts of honey radix stemonae, 12 parts of schisandra chinensis, 14 parts of radix paeoniae rubra and 15 parts of scutellaria baicalensis.
The traditional Chinese medicine composition for treating the chronic obstructive pulmonary disease in the stable phase is prepared by the following steps:
step 1, weighing all the components according to the weight part ratio, and crushing all the components;
step 2, taking the crushed astragalus, rhizoma polygonati, dried orange peel, schisandra chinensis, honey radix stemonae, red paeony root and scutellaria baicalensis, extracting for 2 times by adopting 8-12 times of water according to the weight-volume ratio, and each time lasts for 1-3 hours, combining the extracting solutions, and filtering to obtain a filtrate;
and 3, adsorbing the filtrate obtained in the step 2 by using D101 macroporous resin, eluting by using water and 60-80% ethanol in sequence, collecting ethanol eluent, concentrating the ethanol eluent at 60 ℃ under reduced pressure to obtain an extract with the relative density of 1.10-1.30, drying the extract under reduced pressure at low temperature, and crushing the dried extract to obtain the extract.
The traditional Chinese medicine composition for treating the chronic obstructive pulmonary disease in the stable phase is prepared by the following steps:
step 1, weighing all the components according to the weight part ratio, and crushing all the components;
step 2, extracting crushed sealwort and dried orange peel for 1-3 hours by adopting a steam distillation method to obtain total volatile oil, and performing inclusion by using hydroxypropyl-beta-cyclodextrin according to the weight ratio of 1: 10 to obtain volatile oil inclusion solution;
step 3, mixing the crushed astragalus, honey radix stemonae, schisandra chinensis, red paeony root and scutellaria baicalensis with the residues obtained in the step 2, adding 8-12 times of water for reflux extraction for 2 times, and combining the extracting solutions after 1 hour each time;
step 4, taking the combined extract obtained in the step 3, concentrating the combined extract at 70-90 ℃ under reduced pressure to obtain clear paste with the relative density of 1.10-1.30, precipitating the clear paste with ethanol until the ethanol content is 65-85%, refrigerating the clear paste for 12-48 hours, and separating supernatant;
and 5, taking the supernatant obtained in the step 4, concentrating under reduced pressure at 60-80 ℃ until no alcohol smell exists to obtain a concentrated extract, dispersing by adopting the volatile oil inclusion solution obtained in the step 2, refrigerating for 12-48 hours, filtering, and spray-drying the filtrate to obtain the product.
The Chinese medicinal composition can be made into granule, tablet, capsule, oral liquid, and pill.
Use of a Chinese medicinal composition as defined in any preceding claim in the preparation of a medicament for use in the stable phase of treatment of chronic obstructive pulmonary disease.
The invention has the beneficial effects that:
the invention carries out syndrome differentiation treatment aiming at the pathogenesis of chronic obstructive pulmonary disease, and the astragalus and the rhizoma polygonati in the formula are used as monarch drugs for tonifying lung qi and benefiting spleen qi by strengthening spleen and nourishing lung and regulating qi and reducing phlegm through scientific compatibility according to the lung-tonifying soil to generate lung metal; the dried orange peel and the honey radix stemonae are used as ministerial drugs, and the effects of invigorating spleen, reducing phlegm, moistening lung, descending qi and relieving cough are achieved; fructus Schisandrae chinensis is used as adjuvant drug for invigorating qi, astringing lung, and relieving cough; radix Paeoniae Rubra and Scutellariae radix are used as guiding drugs for promoting blood circulation, clearing heat and eliminating pathogenic factors. The medicines are used together to tonify the lung and the spleen, reduce phlegm and relieve cough, and fully exert the treatment advantages of the traditional Chinese medicine on chronic diseases.
According to the main effective components of the medicines in the prescription, the volatile oil is extracted from the sealwort and the dried orange peel, and then the hydroxypropyl-beta-cyclodextrin inclusion is adopted to retain the volatile components in the subsequent spray drying process. The other medicines are subjected to water extraction and alcohol precipitation treatment, so that the transfer rate of starch and inorganic salt components is reduced, the dosage is reduced, and the preparation is convenient. Meanwhile, the preparation method adopts compound extraction, the astragalus and the schisandra are rich in saponin components, and are easy to associate with fat-soluble small molecules in the rhizoma polygonati and the dried orange peel in the decocting process, so that the component extraction rate and the transfer rate in the subsequent macroporous resin adsorption refining process are improved, the efficient retention of effective components in the traditional Chinese medicine composition is ensured, and the drug effect is ensured. The invention can effectively improve the symptoms of cough and asthma, short breath, little phlegm, cold and the like in the stable period of the chronic obstructive pulmonary disease.
Detailed Description
The following describes in detail embodiments of the present invention in conjunction with the actual situation.
Example 1
20g of astragalus, 16g of rhizoma polygonati, 14g of dried orange peel, 14g of honey radix stemonae, 11g of schisandra chinensis, 14g of red paeony root and 11g of scutellaria baicalensis
The preparation process comprises the following steps:
weighing the components according to the weight part ratio, and crushing all the components; extracting crushed rhizoma polygonati and dried orange peel for 2 hours by adopting a steam distillation method to obtain total volatile oil, and performing inclusion by using hydroxypropyl-beta-cyclodextrin according to the weight ratio of 1: 10 to obtain volatile oil inclusion solution; mixing pulverized radix astragali, radix Stemonae, fructus Schisandrae chinensis, radix Paeoniae Rubra, Scutellariae radix, rhizoma Polygonati, and pericarpium Citri Tangerinae residue, adding 10 times of water, reflux-extracting for 2 times, each for 1 hr, mixing extractive solutions, concentrating under reduced pressure at 80 deg.C to obtain fluid extract with relative density of 1.20, precipitating with ethanol until ethanol content is 75%, refrigerating for 24 hr, collecting supernatant, concentrating under reduced pressure at 60 deg.C until no ethanol smell exists to obtain concentrated extract, dispersing with rhizoma Polygonati and pericarpium Citri Tangerinae volatile oil inclusion solution, refrigerating for 12 hr, filtering, adding appropriate adjuvant, spray drying, and tabletting to obtain tablet.
Example 2
30g of astragalus, 10g of rhizoma polygonati, 20g of dried orange peel, 5g of honey radix stemonae, 15g of schisandra chinensis, 6g of red paeony root and 14g of scutellaria baicalensis
The preparation process comprises the following steps: weighing the components according to the weight part ratio, and crushing all the components; taking crushed astragalus, sealwort, dried orange peel, schisandra, honey stemona root, red peony root and scutellaria baicalensis, extracting for 2 times by 12 times of water according to the weight-volume ratio, each time for 1.5 hours, combining extracting solutions, filtering to obtain a filtrate, adsorbing by using D101 macroporous resin, sequentially eluting by using water and 60% ethanol, collecting ethanol eluent, concentrating under reduced pressure at 60 ℃ to obtain an extract with the relative density of 1.15, drying the extract under reduced pressure at low temperature, crushing, and subpackaging capsules to obtain the capsules.
Example 3
18g of astragalus, 20g of rhizoma polygonati, 6g of dried orange peel, 15g of honey radix stemonae, 12g of schisandra fruit, 14g of red paeony root and 15g of scutellaria baicalensis
The preparation process comprises the following steps: weighing the components according to the weight part ratio, and crushing all the components; extracting crushed rhizoma polygonati and dried orange peel for 3 hours by adopting a steam distillation method to obtain total volatile oil, and performing inclusion by using hydroxypropyl-beta-cyclodextrin according to the weight ratio of 1: 10 to obtain volatile oil inclusion solution; mixing pulverized radix astragali, radix Stemonae, fructus Schisandrae, radix Paeoniae Rubra, Scutellariae radix, rhizoma Polygonati, and pericarpium Citri Tangerinae residue, adding 8 times of water, reflux extracting for 2 times, each for 1 hr, mixing extractive solutions, concentrating under reduced pressure at 70 deg.C to obtain fluid extract with relative density of 1.10, precipitating with ethanol until ethanol content is 65%, refrigerating for 24 hr, collecting supernatant, concentrating under reduced pressure at 60 deg.C until no ethanol smell exists to obtain concentrated extract, dispersing with volatile oil solution, refrigerating for 24 hr, filtering, spray drying filtrate, dissolving with purified water, adding correctant, microfiltering, packaging, and sterilizing to obtain oral liquid.
Example 4
15g of astragalus, 15g of rhizoma polygonati, 15g of dried orange peel, 15g of honey radix stemonae, 15g of schisandra chinensis, 15g of red paeony root and 15g of scutellaria baicalensis
The preparation process comprises the following steps: extracting crushed rhizoma polygonati and dried orange peel for 2 hours by adopting a steam distillation method to obtain total volatile oil, and performing inclusion by using hydroxypropyl-beta-cyclodextrin according to the weight ratio of 1: 10 to obtain volatile oil inclusion solution; mixing pulverized radix astragali, radix Stemonae, fructus Schisandrae chinensis, radix Paeoniae Rubra, Scutellariae radix, rhizoma Polygonati, and pericarpium Citri Tangerinae residue, adding 12 times of water, reflux-extracting for 2 times, each for 1 hr, mixing extractive solutions, concentrating under reduced pressure at 80 deg.C to obtain fluid extract with relative density of 1.25, precipitating with ethanol until ethanol content is 75%, refrigerating for 24 hr, collecting supernatant, concentrating under reduced pressure at 60 deg.C until no ethanol smell exists to obtain concentrated extract, dispersing with rhizoma Polygonati and pericarpium Citri Tangerinae volatile oil inclusion solution, refrigerating for 12 hr, filtering, adding appropriate adjuvant, spray drying, adding appropriate adjuvant, wet granulating, drying at low temperature, and grading to obtain granule.
The therapeutic effect of the medicament on the chronic obstructive pulmonary disease in the stable phase can be further verified by the following clinical case observation.
Example 5 clinical study data
1. Object
Patients diagnosed with chronic obstructive pulmonary disease in acute attack stage are referred to the Chinese medicine syndrome differentiation diagnostics and the Chinese medicine diagnosis and treatment guidelines for chronic obstructive pulmonary disease (2011 edition); (2) patients who meet the diagnosis standard of chronic obstructive pulmonary disease in stable phase in internal medicine (8 th edition). Exclusion criteria: (1) patients who have a possible effect on the outcome of treatment, in combination with other diseases; (2) pregnant women, patients in lactation, and patients with mental disorder; (3) liver and kidney insufficiency may affect the metabolism and excretion of the medicine.
150 patients diagnosed with the stable phase of the chronic obstructive pulmonary disease who are outpatient or hospitalized in my hospital from 2016 to 2017 and 6 are selected (87 in males and 63 in females). 150 patients were randomized into five groups according to the random number method: the age and sex of patients in the control group, the example 1 group, the example 2 group, the example 3 group and the example 4 group are not significantly different (P > 0.05) among the groups of 30 people in each group.
2. Treatment regimens
The treatment course is 8 weeks, and no other medicine is used in the process, if acute onset of chronic obstructive pulmonary disease occurs, a standard treatment scheme in COPD diagnosis and treatment guidelines (revised 2007), conventional controlled oxygen therapy, intravenous drip or oral aminophylline, inhalation antispasmodic agent, antibiotic, phlegm-resolving medicine and the like are adopted. And recalculating the treatment course after the symptom is relieved and enters a stable period.
The control group patients took lily Gujin tablets (manufacturer: Guangzhou Nuojin pharmaceutical Co., Ltd., national Standard Z20050219) five tablets at a time and three times a day.
In the examples, the corresponding preparations in examples 1 to 4 were used, and the daily dose was a prescribed dose.
3. Observation index
3.1 evaluation of clinical efficacy
Refer to the guidelines for diagnosis and treatment of chronic obstructive pulmonary disease (2013 revised edition). Clinical symptoms and signs are obviously improved or basically disappear, and the symptom score is reduced by more than 70 percent to show effect; the clinical symptoms and physical signs are improved, and the symptom score is reduced by 50 to 70 percent to be effective; the above criteria are not met, i.e. clinical symptoms and signs do not improve or even continue to worsen, and the score is not significantly reduced, which is ineffective.
3.2 evaluation of adverse reaction occurrence
The patients in the control group and the patients in the example group were compared for the occurrence of adverse reactions.
3.3 evaluation of patient quality of Life
The quality of life of patients with chronic obstructive pulmonary disease is evaluated by adopting Saint George's Respiratory Questionnaire (SGRQ), and comprises three parts of respiratory symptoms, activity and disease influence.
The respiratory symptoms have 8 questions, and the relevant indexes of the patient are judged by a single choice question, including inquiring about the onset conditions of cough, expectoration, asthma, dyspnea and the like of the patient. The activity and the disease influence are not judgment questions, and the influence of the disease on daily life and work is evaluated.
Respiratory symptoms are divided into 5 points, the latter two points are answered by 'yes' or 'no', the value range is 0-100, the lower the value is, the higher the quality of life of a patient is, and the change of 4 points is considered to have clinical significance.
4. Statistical method
Statistical analysis is carried out by using SPSS 19.0 software, the data are expressed by mean value plus or minus standard deviation, and the statistical significance is realized when P is less than 0.05 by adopting t test.
5. Results
(1) Clinical efficacy comparison between patients in the example group and those in the control group
The total effective rate of the control group is 73.33 percent, the total effective rates of the example groups are all higher than 93 percent, and the difference with the control group has statistical significance (P is less than 0.05), and specific results are shown in table 1.
Table 1 comparison of clinical efficacy (n ═ 30)
Note: p < 0.05 compared to control.
(2) Adverse reaction occurrence
The incidence of adverse reactions of the patients in the example group and the control group during the treatment period is not significantly different (P is more than 0.05), and the results are shown in the table 2, which indicates that no adverse reaction is generated by the control group and the example group after the medicine is taken.
Table 2 adverse reaction occurrence (n ═ 30)
(3) Changes in lung function
The lung function of the patients in the example group and the patients in the control group are improved to a certain degree after receiving the treatment, and the results of the patients in the example group are remarkably different (P is less than 0.05) compared with the results before the treatment; the results of the treatment of the example 1 group and the example 4 group were significantly different (P < 0.05) compared with the control group; the FCV index has significant difference (P < 0.05) after the treatment of the group in example 2 compared with the control group, and the FCV and FEV indexes after the treatment of the group in example 3 compared with the control group1The indexes have significant difference (P is less than 0.05), and the results are shown in Table 3.
Table 3 changes in lung function (n ═ 30)
Note: p < 0.05 compared to the group after treatment; comparison with control group after treatment#P＜0.05。
(4) Comparison of SGRQ scores before and after treatment of patients in the example group and patients in the control group
The results of comparing the SGRQ scores of the patients in the example group with those in the control group before and after treatment are shown in Table 4. After treatment, the SGRQ scores of the patients with the regimens of examples 1-4 and the control patients were improved in respiratory symptoms, activity limitation, disease impact, overall score (P < 0.05) compared to before treatment. EXAMPLES 1-4 dosing regimens patients who had better post-treatment SGRQ scores than controls in terms of respiratory symptoms, disease impact, overall score, and significant differences (P < 0.05)
Table 4 SGRQ scores before and after treatment (n-30) for patients in the example and control groups
Note: p < 0.05 compared to the group after treatment; comparison with control group after treatment#P＜0.05。
The traditional Chinese medicine composition provided by the invention has the effects of strengthening body resistance and consolidating constitution, tonifying lung and spleen, reducing phlegm and relieving cough, regulating internal environment of an organism, exciting self-defense function of the organism, enhancing self-stabilization state of the organism, promoting recovery of a patient and preventing repeated exacerbation of an illness. In clinical use, the life quality of patients in the stable phase of the chronic obstructive pulmonary disease can be remarkably improved.
What is not described in detail in this specification is prior art to the knowledge of those skilled in the art.
Claims (9)
1. A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable period is characterized by comprising the following raw material medicines in parts by weight: 10-30 parts of astragalus membranaceus, 9-20 parts of rhizoma polygonati, 5-20 parts of pericarpium citri reticulatae, 3-15 parts of honey radix stemonae, 4-15 parts of schisandra chinensis, 6-15 parts of radix paeoniae rubra and 3-15 parts of scutellaria baicalensis.
2. The traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable period according to claim 1, which is prepared from the following raw material medicines in parts by weight: 20 parts of astragalus membranaceus, 16 parts of rhizoma polygonati, 14 parts of pericarpium citri reticulatae, 14 parts of honey radix stemonae, 11 parts of schisandra chinensis, 14 parts of radix paeoniae rubra and 11 parts of scutellaria baicalensis.
3. The traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable period according to claim 1, which is prepared from the following raw material medicines in parts by weight: 30 parts of astragalus membranaceus, 10 parts of rhizoma polygonati, 20 parts of pericarpium citri reticulatae, 5 parts of honey radix stemonae, 15 parts of schisandra chinensis, 6 parts of radix paeoniae rubra and 14 parts of scutellaria baicalensis.
4. The traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable period according to claim 1, which is prepared from the following raw material medicines in parts by weight: 18 parts of astragalus membranaceus, 20 parts of rhizoma polygonati, 6 parts of pericarpium citri reticulatae, 15 parts of honey radix stemonae, 12 parts of schisandra chinensis, 14 parts of radix paeoniae rubra and 15 parts of scutellaria baicalensis.
5. The traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable period according to claim 1, which is prepared from the following raw material medicines in parts by weight: 15 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of pericarpium citri reticulatae, 15 parts of honey radix stemonae, 15 parts of schisandra chinensis, 15 parts of radix paeoniae rubra and 15 parts of scutellaria baicalensis.
6. A method for preparing a Chinese medicinal composition for treating chronic obstructive pulmonary disease in the stable phase according to any one of claims 1 to 5, comprising:
step 1, weighing all the components according to the weight part ratio, and crushing all the components;
step 2, taking the crushed astragalus, rhizoma polygonati, dried orange peel, schisandra chinensis, honey radix stemonae, red paeony root and scutellaria baicalensis, extracting for 2 times by adopting 8-12 times of water according to the weight-volume ratio, and each time lasts for 1-3 hours, combining the extracting solutions, and filtering to obtain a filtrate;
and 3, adsorbing the filtrate obtained in the step 2 by using D101 macroporous resin, eluting by using water and 60-80% ethanol in sequence, collecting ethanol eluent, concentrating the ethanol eluent at 60 ℃ under reduced pressure to obtain an extract with the relative density of 1.10-1.30, drying the extract under reduced pressure at low temperature, and crushing the dried extract to obtain the extract.
7. The traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in a stable phase according to claim 1, which is prepared by the following steps:
step 1, weighing all the components according to the weight part ratio, and crushing all the components;
step 2, extracting crushed sealwort and dried orange peel for 1-3 hours by adopting a steam distillation method to obtain total volatile oil, and performing inclusion by using hydroxypropyl-beta-cyclodextrin according to the weight ratio of 1: 10 to obtain volatile oil inclusion solution;
step 3, mixing the crushed astragalus, honey radix stemonae, schisandra chinensis, red paeony root and scutellaria baicalensis with the residues obtained in the step 2, adding 8-12 times of water for reflux extraction for 2 times, and combining the extracting solutions after 1 hour each time;
step 4, taking the combined extract obtained in the step 3, concentrating the combined extract at 70-90 ℃ under reduced pressure to obtain clear paste with the relative density of 1.10-1.30, precipitating the clear paste with ethanol until the ethanol content is 65-85%, refrigerating the clear paste for 12-48 hours, and separating supernatant;
and 5, taking the supernatant obtained in the step 4, concentrating under reduced pressure at 60-80 ℃ until no alcohol smell exists to obtain a concentrated extract, dispersing by adopting the volatile oil inclusion solution obtained in the step 2, refrigerating for 12-48 hours, filtering, and spray-drying the filtrate to obtain the product.
8. The Chinese medicinal composition as claimed in claim 6 or 7, wherein the composition can be prepared into granules, tablets, capsules, oral liquids, and pills.
9. Use of a Chinese medicinal composition as defined in any preceding claim in the preparation of a medicament for use in the stable phase of treatment of chronic obstructive pulmonary disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910539996 | 2019-06-21 | ||
| CN2019105399966 | 2019-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111588757A true CN111588757A (en) | 2020-08-28 |
Family
ID=72181451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911211189.8A Pending CN111588757A (en) | 2019-06-21 | 2019-12-02 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111588757A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113116986A (en) * | 2021-05-31 | 2021-07-16 | 广州医科大学附属第一医院（广州呼吸中心） | Traditional Chinese medicine composition for chronic obstructive pulmonary disease rehabilitation period and application thereof |
| CN116036040A (en) * | 2022-11-28 | 2023-05-02 | 四川省中医药科学院中医研究所 | Lung-tonifying granule and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188602A (en) * | 2011-05-09 | 2011-09-21 | 河南中医学院 | Traditional Chinese medicine particles for treating syndrome of insufficiency of lung and kidney qi caused by chronic obstructive disease of lung |
| CN102258688A (en) * | 2011-07-21 | 2011-11-30 | 河南中医学院 | Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD) |
| CN107648468A (en) * | 2017-11-14 | 2018-02-02 | 上海市静安区中医医院 | A kind of Chinese medicine composition for treating COPD and its application |
-
2019
- 2019-12-02 CN CN201911211189.8A patent/CN111588757A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188602A (en) * | 2011-05-09 | 2011-09-21 | 河南中医学院 | Traditional Chinese medicine particles for treating syndrome of insufficiency of lung and kidney qi caused by chronic obstructive disease of lung |
| CN102258688A (en) * | 2011-07-21 | 2011-11-30 | 河南中医学院 | Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD) |
| CN107648468A (en) * | 2017-11-14 | 2018-02-02 | 上海市静安区中医医院 | A kind of Chinese medicine composition for treating COPD and its application |
Non-Patent Citations (2)
| Title |
|---|
| 许银姬: "晁恩祥教授治疗慢性阻塞性肺病经验拾萃 ", 《辽宁中医药大学学报》 * |
| 郑元俊: "中西医结合治疗慢性阻塞性肺疾病82例 ", 《实用中医药杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113116986A (en) * | 2021-05-31 | 2021-07-16 | 广州医科大学附属第一医院（广州呼吸中心） | Traditional Chinese medicine composition for chronic obstructive pulmonary disease rehabilitation period and application thereof |
| CN116036040A (en) * | 2022-11-28 | 2023-05-02 | 四川省中医药科学院中医研究所 | Lung-tonifying granule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021120972A1 (en) | Traditional chinese medicine composition for treating deficiency of both qi and blood, preparation method therefor and use thereof | |
| CN111588757A (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof | |
| CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
| CN111905051A (en) | Traditional Chinese medicine composition with functions of preventing and treating chronic heart failure, qi and yin deficiency, blood stasis and water retention syndrome and preparation method and application thereof | |
| CN106138668A (en) | A kind of Chinese medicine composition treating COPD and preparation method thereof | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| US10857186B2 (en) | Traditional Chinese medicine composition for treating acute stage of cerebral infarction | |
| CN109771632B (en) | Pharmaceutical composition for treating chronic obstructive pulmonary disease in stable phase and preparation method and application thereof | |
| CN111743942A (en) | Traditional Chinese medicine composition for treating acute exacerbation of chronic obstructive pulmonary disease and preparation method thereof | |
| CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN1242800C (en) | Chinese medicine prepn for treating deficiency of spleen and stomach Yin type atrophic gastritis | |
| US20190167731A1 (en) | Traditional Chinese Medicine Composition for Treating Acute Stage of Cerebral Infarction | |
| CN109908294B (en) | Pharmaceutical composition for treating stable stage of bronchiectasis and preparation method and application thereof | |
| CN101829213B (en) | Medicine composition for treating asthma and preparation method thereof | |
| CN113181259B (en) | Children's astragalus-ginseng cold-treating granule and its prepn | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN113827683A (en) | Traditional Chinese medicine compound composition for treating hyperthyroidism and preparation method and application thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN107233430B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN116474023A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicines with function of treating/preventing chronic obstructive pulmonary disease | |
| CN117414387A (en) | Traditional Chinese medicine composition for preventing and treating subalternation pulmonary nodules as well as preparation method and application thereof | |
| CN113648381A (en) | Traditional Chinese medicine composition for bronchiectasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200828 |
|
| WD01 | Invention patent application deemed withdrawn after publication |